Electromed, Inc. (NYSE:ELMD) Q2 2021 Earnings Conference Call February 9, 2021 5:00 PM ET Company Participants Devin Sullivan - IR Kathleen Skarvan - CEO, President & Director Michael MacCourt - CFO, Treasurer & Secretary Conference Call Participants Kyle Bauser - Colliers Securities James Terwilliger - Northland Capital Markets Operator Greetings, and welcome to the Electromed Second Quarter Fiscal 2021 Financial Results Conference Call. [Operator Instructions]. As a reminder, this conference is being reco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-34839 Electromed, Inc. (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |------------ ...

Financial Data and Key Metrics Changes - In Q1 fiscal 2021, overall net revenue was $8 million, a decrease of 3.6% compared to the same period last year [7][21] - Net income was approximately $535,000, or $0.06 per diluted share, down from $1 million, or $0.12 per diluted share in the prior year [13][29] - Gross profit dollars decreased by 3.1% to $6.1 million, representing 76.8% of net revenue [24] Business Line Data and Key Metrics Changes - Home care revenue was approximately $7.5 million, remaining flat year-over-year, but increased by 17.9% compared to the previous quarter [21] - Institutional revenue decreased by 55.5% year-over-year to $278,000 due to reduced hospital purchases related to COVID-19 [22] - Distributor revenue increased by 48.3% to $178,000 from $120,000 in the first quarter of fiscal 2020 [23] Market Data and Key Metrics Changes - International revenue totaled $84,000, up from $66,000 in the prior year period, although it is not a strategic growth area for the company [23] - The home care business benefited from the CMS waiver, which has been extended, aiding revenue growth [9] Company Strategy and Development Direction - The company aims to strengthen its institutional strategy by fortifying hospital call points and partnerships with integrated delivery networks [11] - There is a focus on expanding the sales organization and investing in direct-to-consumer marketing to increase awareness of bronchiectasis and SmartVest [14][54] - The long-term growth thesis remains intact, targeting a significant market opportunity in non-cystic fibrosis bronchiectasis [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about resuming long-term low double-digit revenue growth as the impact of COVID-19 abates [19] - The company remains committed to maintaining profitability and has not experienced significant disruptions in manufacturing or supply chain [15][30] Other Important Information - The company appointed Kristine Owata as Vice President of Reimbursement and Payer Relations, bringing 15 years of experience [16][17] - R&D expenses increased significantly to $481,000, primarily for next-generation product development [27] Q&A Session Summary Question: Will the CMS waiver be extended beyond January? - Management indicated there is a good chance the waiver may be extended based on COVID-19 case trends [32][33] Question: What are the plans for capital allocation? - Management stated that all options, including acquisitions and dividends, are on the table, but priority will be given to strategies for accelerating growth [34][36] Question: What is the status of the multicenter study? - The study is underway with enrollment ongoing, and it aims to include quality of life surveys, which are recognized by the FDA as important outcomes [38][40] Question: How will R&D spending be managed going forward? - R&D spending is expected to remain at similar levels for the duration of fiscal 2021 [45] Question: What is the outlook for SG&A expenses? - Management plans to expand the sales organization and invest in infrastructure to support future growth [54]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-34839 Electromed, Inc. (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |----------- ...

Electromed, Inc. (NYSE:ELMD) Q4 2020 Results Earnings Conference Call August 25, 2020 5:00 PM ET Company Participants Kalle Ahl - IR, The Equity Group Inc. Kathleen Skarvan - President and Chief Executive Officer Mike MacCourt - Chief Financial Officer Conference Call Participants Kyle Bauser - Colliers Securities Operator Greetings and welcome to Electromed Inc.'s Fourth Quarter and Full Year Fiscal 2020 Financial Results Conference Call. At this time all participants are in a listen-only mode. A question- ...

Revenue Performance - Revenue for the fiscal year ended June 30, 2020, is summarized in thousands of dollars, indicating a comparison with the previous fiscal year[142]. - Total revenue for fiscal 2020 was approximately $32,471,000, an increase of 3.7% compared to $31,300,000 in fiscal 2019[143]. - Home care revenue increased by 1.3%, or approximately $374,000, for fiscal 2020, driven by a higher percentage of approved referrals[143]. - Institutional revenue rose by 24.7%, or approximately $396,000, in fiscal 2020, primarily due to higher selling prices and an increase in the number of devices sold[144]. Profitability and Expenses - Gross profit for fiscal 2020 was approximately $25,200,000, representing 77.6% of net revenues, up from 76.2% in fiscal 2019[148]. - Selling, general and administrative expenses decreased by approximately $490,000, or 2.4%, to approximately $19,945,000 in fiscal 2020[150]. - Research and development expenses were approximately $1,050,000, or 3.2% of net revenues, for fiscal 2020, with expectations for a slight increase in spending for fiscal 2021[156]. - Net income for fiscal 2020 was approximately $4,161,000, compared to $1,980,000 in fiscal 2019, driven by increased gross profit and government stimulus income[163]. Government Assistance and Impact of COVID-19 - The company received a stimulus payment of approximately $913,000 under the CARES Act to offset revenue losses due to the COVID-19 pandemic[129]. - The COVID-19 pandemic has negatively impacted institutional revenue as hospitals adjusted their operating protocols, affecting procurement management[123]. - The company initiated cost-containment measures in response to the COVID-19 pandemic, including reducing discretionary spending and employee furloughs[126]. - The company recorded $913,000 of government stimulus income related to the COVID-19 pandemic in fiscal 2020[158]. Product Information and Market Strategy - The SmartVest SQL product has been sold in the domestic home care market since 2014, with enhancements in programmability and ease of use compared to the previous model[116]. - The company employs a direct-to-patient and provider model, allowing it to capture both manufacturer and distributor margins[118]. - The SmartVest System is often eligible for reimbursement from major private insurance providers, which is crucial for patient access to therapy[117]. - The company aims to expand its clinical evidence base to increase utilization of the SmartVest for patients with bronchiectasis[119]. - Key growth strategies for fiscal 2021 include increasing referrals in adult pulmonology/bronchiectasis and enhancing patient and provider support[119]. Financial Metrics and Adjustments - Cash flows from operating activities for fiscal 2020 were approximately $4,196,000, consisting of net income and non-cash expenses[164]. - The effective tax rate for fiscal 2020 was 20.6%, down from 32.3% in fiscal 2019, influenced by various tax credits and deductions[162]. - Net revenues for the twelve months ended June 30, 2019, were reported at $31,299,750, with no adjustments made[176]. - Gross profit for the same period was $23,847,944, indicating a strong revenue generation capability[176]. - Operating income adjusted to $2,829,623 after accounting for the adoption of ASC 842, reflecting an increase of $11,112[176]. - The net income for the twelve months ended June 30, 2019, was reported at $1,980,330, after adjustments[176]. - Basic earnings per share remained at $0.24, with diluted earnings per share also unchanged at $0.23[176]. - Total operating expenses were adjusted to $21,018,321, with selling, general, and administrative expenses slightly reduced to $20,435,010[176].

Electromed, Inc. (NYSE:ELMD) Q3 2020 Earnings Conference Call May 13, 2020 8:30 AM ET Company Participants Kalle Ahl - Investor Relations Kathleen Skarvan - President and Chief Executive Officer Jeremy Brock - Chief Financial Officer Conference Call Participants Kyle Bauser - Dougherty & Company Operator Greetings and welcome to the Electromed Third Quarter Fiscal 2020 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-34839 Electromed, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 41-1732920 (State or other ...

Electromed, Inc. (NYSE:ELMD) Q2 2020 Earnings Conference Call February 12, 2020 8:30 AM ET Company Participants Kalle Ahl – Vice President-The Equity Group Kathleen Skarvan – President and Chief Executive Officer Jeremy Brock – Chief Financial Officer Conference Call Participants Kyle Bauser – Dougherty & Company Howard Rue – Private Investor Operator Greetings, and welcome to the Electromed, Inc.'s Second Quarter Fiscal 2020 Fiscal Results Conference Call. [Operator Instructions] As a reminder, this confer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-34839 Electromed, Inc. (Exact Name of Registrant as Specified in its Charter) Indicate by check mark whether th ...